Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.

OBJECTIVE To evaluate the contribution of metabolites (methotrexate [MTX] and folate polyglutamate [PG] levels) and pharmacogenetic biomarkers in the folate pathway to the effects of MTX in patients with rheumatoid arthritis not previously treated with this antifolate. METHODS Forty-eight MTX-naive adult patients were enrolled in a prospective longitudinal study. MTX therapy was initiated at 7.5 mg/week and was increased every 4-6 weeks until a therapeutic response was achieved. Response was assessed using the Disease Activity Score in 28 joints (DAS28). Red blood cell (RBC) MTX and folate PG levels were measured with 9 common polymorphisms in the folate pathway. Statistical analyses consisted of generalized linear models and multivariate regressions. RESULTS After 6 months of therapy, the median weekly MTX dosage was 17.5 mg and the median decrease in the DAS28 was 2.0. There was a large interpatient variability in RBC MTXPG levels (median 35 nmoles/liter [interquartile range 28-51] at month 6). Patients with a lesser decrease in the DAS28 (fewer improvements) had lower RBC MTXPG levels (P < 0.05) despite the higher MTX dose administered (P < 0.05). RBC folate PG levels decreased significantly during treatment, and a lesser decrease in RBC folate PGs was associated with a lesser decrease in the DAS28 (P < 0.05). Primary side effects were gastrointestinal and neurologic in nature. Risk genotypes associated with toxicity were in gamma-glutamyl hydrolase (-401CC), 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (347GG), methylenetetrahydrofolate reductase (1298AC/CC), methionine synthase (2756AA), and methionine synthase reductase (66GG). CONCLUSION RBC MTXPG levels are a useful means by which to monitor therapy. The genetic associations presented generate hypotheses, and confirmation in independent cohorts is warranted.

[1]  H. Paulus,et al.  Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. , 2005, Arthritis and rheumatism.

[2]  G. Peters,et al.  Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. , 2005, Blood.

[3]  B. Meshkin,et al.  Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. , 2005, Mutation research.

[4]  T. Ahmad,et al.  The pharmacogenetics of methotrexate in inflammatory bowel disease. , 2005, Pharmacogenetics & Genomics.

[5]  T. Rebbeck,et al.  Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. , 2005, Cancer research.

[6]  J. Kremer,et al.  Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study , 2005, Annals of the rheumatic diseases.

[7]  S. Miriuka,et al.  Genetic polymorphisms predisposing to hyperhomocysteinemia in cardiac transplant patients , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[8]  G. Alarcón,et al.  The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[9]  D. Mevorach,et al.  Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene , 2004, Annals of the rheumatic diseases.

[10]  Katie Smith,et al.  Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[11]  B. Ames,et al.  Folate Deficiency Inhibits the Proliferation of Primary Human CD8+ T Lymphocytes In Vitro1 , 2004, The Journal of Immunology.

[12]  J. Kremer.  Toward a better understanding of methotrexate. , 2004, Arthritis and rheumatism.

[13]  M. Lucock,et al.  Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. , 2004, Journal of the National Cancer Institute.

[14]  J. Marcelletti,et al.  HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. , 2003, Clinical chemistry.

[15]  A. Evans,et al.  Corrigendum to “The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations” [ATH 157 (2001) 451–456] , 2003 .

[16]  J. Fries,et al.  The methotrexate therapeutic response in rheumatoid arthritis. , 2002, The Journal of rheumatology.

[17]  M. Relling,et al.  De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. , 2002, Blood.

[18]  G. Morgan,et al.  Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. , 2002, Blood.

[19]  C. Ulrich,et al.  Pharmacogenetics and folate metabolism -- a promising direction. , 2002, Pharmacogenomics.

[20]  A. Aro,et al.  Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. , 2001, The Journal of nutrition.

[21]  A. Evans,et al.  The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. , 2001, Atherosclerosis.

[22]  H. Blom,et al.  Is mutated serine hydroxymethyltransferase (SHMT) involved in the etiology of neural tube defects? , 2001, Molecular genetics and metabolism.

[23]  D. Hunter,et al.  Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. , 2001, Atherosclerosis.

[24]  A. Evans,et al.  Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations , 1999, Genetic epidemiology.

[25]  P. Angelis-Stoforidis,et al.  Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. , 1999, Clinical and experimental rheumatology.

[26]  D. Felson,et al.  ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. , 1999, The Journal of rheumatology.

[27]  M. Šimková,et al.  Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment , 1998, European Journal of Clinical Pharmacology.

[28]  G. Alarcón,et al.  Supplementation with Folic Acid during Methotrexate Therapy for Rheumatoid Arthritis: A Double-Blind, Placebo-Controlled Trial , 1994, Annals of Internal Medicine.

[29]  J. Kremer,et al.  Methotrexate for rheumatoid arthritis : suggested guidelines for monitoring liver toxicity , 1994 .

[30]  J. Kremer,et al.  Methotrexate for Rheumatoid Arthritis , 1994 .

[31]  B. Cronstein,et al.  The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. , 1993, The Journal of clinical investigation.

[32]  M. A. van 't Hof,et al.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. , 1990, Annals of the rheumatic diseases.

[33]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[34]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[35]  J. Kremer,et al.  The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[36]  G. Curt,et al.  Polyglutamation of methotrexate. Is methotrexate a prodrug? , 1985, The Journal of clinical investigation.

[37]  M. Weinblatt,et al.  Efficacy of low-dose methotrexate in rheumatoid arthritis. , 1985, The New England journal of medicine.

[38]  J. Gregory,et al.  Effect of food fortification on folic acid intake in the United States. , 2003, The American journal of clinical nutrition.

[39]  M. Suarez‐Almazor,et al.  The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. , 1998, The Journal of rheumatology.

[40]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.